Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announce that they have entered into a definitive agreement for Servier to acquire Day One for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. This acquisition will reinforce Servier’s position in oncology targeted therapies in line with its 2030 ambition to develop innovative treatments for patients with high unmet medical needs.
Read the full article: Servier and Day One Biopharmaceuticals Announce Acquisition to Expand Servier’s Rare Oncology Portfolio //
Source: https://www.globenewswire.com/news-release/2026/03/06/3251033/0/en/Servier-and-Day-One-Biopharmaceuticals-announce-acquisition-to-expand-Servier-s-rare-oncology-portfolio.html?_gl=1*16d4w6t*_up*MQ..*_ga*MjExNDgyMDQwMC4xNzcyODA2MTA1*_ga_B6167QB2TF*czE3NzI4MDYxMDUkbzEkZzAkdDE3NzI4MDYxMDUkajYwJGwwJGgw*_ga_ERWPGTJ5X8*czE3NzI4MDYxMDUkbzEkZzAkdDE3NzI4MDYxMDUkajYwJGwwJGgw